| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Austin Research Institute, Austin Hospital, Heidelberg 3084, Victoria, Australia
Second generation antibodies to mammary mucins were produced by immunizing mice with a peptide with a sequence deduced from that of the MUC1 complementary DNA sequence (PAHGVTSAPDTRPAPGSTAP). Four monoclonal antibodies (BCP7–10) were produced which gave different reactions. BCP8 was similar in tissue reactivity (by immunoper-oxidase staining) to anti-breast cancer or anti-human milk fat globule membranes (HMFG) antibodies and reacted strongly with most breast cancers and a proportion of other adenocarcinomas, whether formalin fixed or fresh, and reacted less strongly with some normal tissues. The three other antibodies (BCP7, BCP9, BCP10) reacted only with fresh tissues or a single cell line (LS174T of colon cancer origin) and gave variable weak reactions. Like many anti-mucin antibodies BCP8 reacted with HMFG, but more strongly with deglycosylated HMFG; analysis with peptides by enzyme-linked immunosorbent assay indicated reactivity with an epitope contained in the amino acid motif PDTR and using the pepscan method, the minimum epitope was DTR. MAbs BCP7, BCP9, and BCP10 did not react with HMFG; substantial reactions were obtained with deglycosylated HMFG for BCP7 and weaker reactions with BCP9 and BCP10. The finding that BCP7 reacted with breast cancer tissues and deglycosylated HMFG suggested that the epitope recognized by BCP7 was masked in native form and exposed in cancer, indicating that BCP7 could be a useful agent for analyzing differences between normal and cancer mucins. The amino acid epitopes for these antibodies were VTSA (BCP7), GSTAP (BCP9), and RPAP (BCP10). For BCP8, amino acid substitution analysis of SAPDTR indicated that substitutions were poorly tolerated (except Q for T and L/Y for R), contrasting with the substitution analysis of anti-mucin antibody reactions where virtually any amino acid can be substituted for T, indicating that in the native state T (threonine) may be O-glycosylated. The use of synthetic peptides to produce antibodies similar to those produced using crude mucins or tumor extracts represents a major advance in the production of antitumor reagents.
1 To whom requests for reprints should be addressed.
Received 9/26/91. Accepted 2/11/92.
This article has been cited by other articles:
|
|
 |
|
  M. Imai, R. Ohta, J. C. Varela, H. Song, and S. Tomlinson Enhancement of Antibody-Dependent Mechanisms of Tumor Cell Lysis by a Targeted Activator of Complement Cancer Res., October 1, 2007; 67(19): 9535 - 9541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Tarp, A. L. Sorensen, U. Mandel, H. Paulsen, J. Burchell, J. Taylor-Papadimitriou, and H. Clausen Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat Glycobiology, February 1, 2007; 17(2): 197 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Longman, R. Poulsom, A. P. Corfield, B. F. Warren, N. A. Wright, and M. G. Thomas Alterations in the Composition of the Supramucosal Defense Barrier in Relation to Disease Severity of Ulcerative Colitis J. Histochem. Cytochem., December 1, 2006; 54(12): 1335 - 1348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Hong, J. Yan, J. T. Baran, D. J. Allendorf, R. D. Hansen, G. R. Ostroff, P. X. Xing, N.-K. V. Cheung, and G. D. Ross Mechanism by Which Orally Administered {beta}-1,3-Glucans Enhance the Tumoricidal Activity of Antitumor Monoclonal Antibodies in Murine Tumor Models J. Immunol., July 15, 2004; 173(2): 797 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Hong, R. D. Hansen, J. Yan, D. J. Allendorf, J. T. Baran, G. R. Ostroff, and G. D. Ross {beta}-Glucan Functions as an Adjuvant for Monoclonal Antibody Immunotherapy by Recruiting Tumoricidal Granulocytes as Killer Cells Cancer Res., December 15, 2003; 63(24): 9023 - 9031. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Vlad, S. Muller, M. Cudic, H. Paulsen, L. Otvos Jr., F.-G. Hanisch, and O. J. Finn Complex Carbohydrates Are Not Removed During Processing of Glycoproteins by Dendritic Cells: Processing of Tumor Antigen MUC1 Glycopeptides for Presentation to Major Histocompatibility Complex Class II-restricted T Cells J. Exp. Med., December 2, 2002; 196(11): 1435 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P A Sylvester, M Walsh, N Myerscough, B F Warren, A P Corfield, M G Thomas, and P Durdey Mucin gene expression in the ileoanal reservoir is altered and may be relevant to the risk of inflammation and dysplasia Gut, September 1, 2002; 51(3): 386 - 391. [Abstract] [Full Text]
|
|
|
|
|
|
G S Arul, M Moorghen, N Myerscough, D A Alderson, R D Spicer, and A P Corfield Mucin gene expression in Barrett's oesophagus: an in situ hybridisation and immunohistochemical study Gut, December 1, 2000; 47(6): 753 - 761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Baruch, M.-l. Hartmann, M. Yoeli, Y. Adereth, S. Greenstein, Y. Stadler, Y. Skornik, J. Zaretsky, N. I. Smorodinsky, I. Keydar, et al. The Breast Cancer-associated MUC1 Gene Generates Both a Receptor and Its Cognate Binding Protein Cancer Res., April 1, 1999; 59(7): 1552 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Apostolopoulos, G. Chelvanayagam, P.-X. Xing, and I. F. C. McKenzie Anti-MUC1 Antibodies React Directly with MUC1 Peptides Presented by Class I H2 and HLA Molecules J. Immunol., July 15, 1998; 161(2): 767 - 775. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
